Effect of aspirin on schizophrenia
Not Applicable
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT2016010725892N1
- Lead Sponsor
- Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
The inclusion criteria were age of 18-65 years old; diagnosed with schizophrenia based on clinical interview and DSM-IV-TR; patients with 2 years of history since the onset of the disease. The exclusion criteria were unwillingness to participate in the study; failure to see doctor for follow-up for whatever reason; unstable medical illness and medical history; contraindications for use of aspirin, such as asthma or seasonal allergies, ulcers, kidney disease, active bleeding or clotting of blood disorders such as hemophilia or bleeding, gout, nasal polyps; chronic use of NSAID; concomitant use of corticosteroids for any reason and maternity.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PANSS test. Timepoint: On the first day, at the end of the sixth week and one month after cessation of aspirin or placebo. Method of measurement: PANSS test.
- Secondary Outcome Measures
Name Time Method